End-Stage Renal Disease
Conditions
Interventions
Control Group:Received Haikun Shenxi Capsules
Treatment group:Received Compound Danshen Injection
Combined group:The combination group was treated with Hekun Nephroprotective Capsules in combination with an SGLT-2 inhibitor, specifically Canagliflozin tablets, similar to the treatment group.
Sponsors
The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Meet the diagnostic criteria for ESRD; 2.Have signed informed consent forms; 3.Possess good cognitive function and the ability to communicate effectively.
Exclusion criteria
Exclusion criteria: 1.Individuals with mental disorders; 2.Those accompanied by severe organic lesions ; 3.Individuals with primary or spontaneous autoimmune disorders; 4.Those with congenital heart disease; 5.Those accompanied by severe infectious diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood Urea Nitrogen;Serum Creatinine;Endogenous Creatinine Clearance;24-hour Urine Protein Excretion;Plasma fibronectin;serum hyaluronic acid;Serum laminin ;Plasma type III procollagen;High-sensitivity C-reactive protein ;Tumor necrosis factor-alpha ;Vascular cell adhesion molecule -1;Monocyte chemotactic protein-1 ;Proteinuria; | — |
Countries
China
Contacts
Public ContactShaohua Cui
The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology
Outcome results
None listed